Plain-English translation of NCT05489289 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help prevent liver cancer from coming back after you've had surgery to remove it. Half of the participants will receive as an injection every three weeks, and the other half will receive a placebo (a dummy injection with no active drug). Researchers want to know if this medication can reduce the chance that your cancer will return.
Even after successful surgery to remove liver cancer, the disease can come back in some patients—especially those with high-risk features. This trial exists to see whether this medication can lower that recurrence risk and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive either or a placebo as an intravenous injection every three weeks. Throughout the trial, you'll have regular clinic visits for check-ups, blood tests, and imaging scans (CT or MRI) to monitor your liver and watch for any signs of cancer returning. The trial will continue until the researchers have enough information to determine whether this medication is effective at preventing recurrence.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Akeso
Enrollment target
~570 participants
Started
January 2023
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Liu, M.D.
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.